Masitinib demonstrates anti‐proliferative and pro‐apoptotic activity in primary and metastatic feline injection‐site sarcoma cells*
- 25 August 2011
- journal article
- research article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 10 (2) , 143-154
Abstract
Dysregulation of platelet-derived growth factor receptor (PDGFR) may play a role in feline injection-site sarcoma (ISS) cell growth and viability. Masitinib, a tyrosine kinase inhibitor approved for treatment of canine mast cell tumours, is highly selective for the PDGFR signalling pathway and may offer a new therapeutic approach for this disease. The in vitro effects of masitinib on growth, apoptosis and PDGFR signalling in two novel ISS cell lines were investigated. PDGFR expression was confirmed by Western blot in cell lines derived from a primary ISS tumour (JB) and a corresponding, histologically confirmed ISS lung metastasis (JBLM). Masitinib inhibited cell growth and PDGFR phosphorylation in both cell lines. Higher drug concentrations were required to inhibit growth than to modulate ligand-induced autophosphorylation of PDGFR. These in vitro data suggest that masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS.Keywords
This publication has 47 references indexed in Scilit:
- Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a studyAmerican Journal of Hematology, 2010
- Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)European Journal of Cancer, 2010
- Prognostic Value of Histologic and Immunohistochemical Features in Feline Cutaneous Mast Cell TumorsVeterinary Pathology, 2010
- Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse ModelPLOS ONE, 2010
- Targeting the cancer kinome through polypharmacologyNature Reviews Cancer, 2010
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KITPLOS ONE, 2009
- Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersEuropean Journal of Cancer, 2009
- A retrospective analysis of radiation therapy for the treatment of feline vaccine‐associated sarcoma*Veterinary and Comparative Oncology, 2009
- Outcome following surgical removal of nonvisceral soft tissue sarcomas in cats: 42 cases (1992–2000)Journal of the American Veterinary Medical Association, 2005
- Vaccine-Associated Sarcomas in CatsClinical Orthopaedics and Related Research, 2001